About this trial
The study aims to evaluate the prevalence of thyroid disease, particularly with autoimmune pathogenesis (isolated hyperthyrotropinemia, hyperthyroidism, hypothyroidism, thyroid nodules) and/or morphostructural abnormalities of the thyroid gland in patients with RASopathy genetically confirmed by NGS technique (analysis of the genes: BRAF, CBL, HRAS, KRAS, LZTR1, MAP2K1, MAP2K2, MRAS, NRAS, PPP1CB, PTPN11, RAF1, RIT1, RRAS2, SHOC2, SOS1, SOS2) and to compare the data obtained in our sample with those of the general population.
The secondary aim of the study is to evaluate the association between vitamin D deficiency and/or other abnormalities of bone metabolism and thyroid disease and/or morphostructural anomalies of the thyroid gland in patients with RASopathy.
Eligibility criteria
Qualifiers
Genetically confirmed RASopathy
Age 3-25 years
Disqualifiers
Previous radiotherapy treatments, known exposure to ionizing radiation
Iodine deficiency
Use of iodine-based compounds or drugs that interfere with thyroid function
Congenital hypothyroidism/hyperthyroidism
Trial design
Treatments tested in this trial
- Not listed